Adipose derived stem cells to construct parathyroid organoid for hypoparathyroidism.
Chen X., Sun J., Li X.
Laboratory Study, published in Med Hypotheses (2021) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Med Hypotheses (2021)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 33618246
- DOI
- 10.1016/j.mehy.2021.110540
Abstract (original English)
Hypoparathyroidism is one of the most common postoperative complications of thyroid surgery, and organoid transplantation is a frontier field expected to treat hypoparathyroidism. Organoids are three-dimensional cell aggregates derived from embryonic stem cells, pluripotent stem cells, or tissue precursor cells, possessing similar structures and functions to organs. Thus they can replace diseased organs to play a role. Adipose-derived stem cells (ASCs) are a population of postnatal stem cells residing in the fat tissue, capable of differentiating into parathyroid-like cells with parathyroid hormone secretion function. Additionally, we have prepared cartilaginous organoids by intelligent porous hydrogel and differentiated ASCs via "bottom-up" strategy in vitro. Therefore, we speculate that parathyroid organoids can be achieved by the biomaterial-assisted assembly of differentiated adipose stem cells and it is a promising treatment for hypoparathyroidism.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.